País: Reino Unido
Língua: inglês
Origem: MHRA (Medicines & Healthcare Products Regulatory Agency)
Memantine hydrochloride
Lupin Healthcare (UK
N06DX01
Memantine hydrochloride
20mg
Tablet
Oral
No Controlled Drug Status
Valid as a prescribable product
BNF: ; GTIN: 8901107024833
PACKAGE LEAFLET: INFORMATION FOR THE USER MEMANTINE HYDROCHLORIDE LUPIN 5MG + 10MG + 15MG + 20MG FILM-COATED TABLETS, TITRATION PACK Memantine hydrochloride READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Memantine tablets are and what they are used for 2. What you need to know before you take Memantine tablets 3. How to take Memantine tablets 4. Possible side effects 5. How to store Memantine tablets 6. Contents of the pack and other information 1. WHAT MEMANTINE TABLETS ARE AND WHAT THEY ARE USED FOR Memantine tablets belongs to a group of medicines known as anti-dementia medicines. Memory loss in Alzheimer’s disease is due to a disturbance of message signals in the brain. The brain contains so-called N-methyl-D-aspartate (NMDA)-receptors that are involved in transmitting nerve signals important in learning and memory. Memantine tablets belongs to a group of medicines called NMDA receptor antagonists. Memantine tablets acts on these NMDA-receptors improving the transmission of nerve signals and the memory. • Memantine tablets are used for the treatment of patients with moderate to severe alzheimer’s disease. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE MEMANTINE TABLETS. DO NOT TAKE MEMANTINE TABLETS: - if you are allergic to memantine hydrochloride or any of the other ingredients of this medicine (listed in section 6). If you are not sure, talk to your doctor or pharmacist before taking Memantine tablets. WARNINGS AND PRECAUTIONS Talk to your doctor or pharmacist before taking Memantine tab Leia o documento completo
OBJECT 1 MEMANTINE HYDROCHLORIDE LUPIN 5MG, 10 MG, 15 MG & 20 MG FILM-COATED TABLETS, TITRATION PACK Summary of Product Characteristics Updated 08-Oct-2015 | Lupin Healthcare (UK) Ltd 1. Name of the medicinal product Memantine hydrochloride Lupin 5mg film-coated tablets Memantine hydrochloride Lupin 10mg film-coated tablets Memantine hydrochloride Lupin 15mg film-coated tablets Memantine hydrochloride Lupin 20mg film-coated tablets 2. Qualitative and quantitative composition Each film-coated tablet contains 5mg of memantine hydrochloride equivalent to 4.15mg memantine. Each film-coated tablet contains 10mg of memantine hydrochloride equivalent to 8.31mg memantine. Each film-coated tablet contains 15mg of memantine hydrochloride equivalent to 12.46mg memantine. Each film-coated tablet contains 20mg of memantine hydrochloride equivalent to 16.62mg memantine. For a full list of excipients, see section 6.1. 3. Pharmaceutical form Film-coated tablets. Memantine 5mg tablets are white to off white coloured, approximately 10 x 4 mm, capsule shaped, biconvex, film-coated tablets, debossed with 5 on one side and plain on the other side. Memantine 10mg tablets are white to off white coloured, approximately 11 x 6 mm, oval shaped, film- coated tablets, debossed with 10 on one side and breakline on the other side. Memantine 15mg tablets are mustard yellow coloured, approximately 14 x 7 mm, oval shaped, film- coated tablets, debossed with 15 on one side and plain on the other side. Memantine 20mg tablets are brownish pink coloured, approximately 14 x 7 mm, oval shaped, film-coated tablets, debossed with 20 on one side and breakline on the other side Memantine 10mg and 20mg tablets can be divided into equal doses. 4. Clinical particulars 4.1 Therapeutic indications Treatment of patients with moderate to severe Alzheimer's disease. 4.2 Posology and method of administration Treatment should be initiated and supervised by a physician experienced in the diagnosis and treatment of Alzheimer's dementia. Therap Leia o documento completo